体外受精（IVF）サービスの世界市場 - 2025年～2032年

体外受精（IVF）サービスの世界市場は2024年に249億1,000万米ドルに達し、2032年には480億4,000万米ドルに達すると予測され、予測期間2025年～2032年のCAGRは8.6%で成長する見込みです。

体外受精（IVF）サービス体外受精とは、体外で卵子と精子を結合させることにより受精を促進する医療処置であり、通常は実験室環境で行われます。体外」とは「ガラスの中」と訳され、受精プロセスが人体内ではなく管理された環境で行われることを意味します。体外受精のプロセスは一般的に、卵巣刺激、採卵、受精、胚培養、胚移植を含むいくつかの重要なステップで構成されています。

体外受精は、高齢出産、卵管閉塞、男性不妊、子宮内膜症、原因不明不妊など、さまざまな不妊の原因に対処するために行われます。この方法は、不妊に関する課題に直面したとき、妊娠を望む多くのカップルにとって不可欠な選択肢となっています。これらの要因によって、世界の体外受精（IVF）サービス市場は拡大しています。

市場力学：

促進要因と抑制要因

不妊症の発生率の増加

不妊症の発生率の増加が体外受精（IVF）サービスの世界市場の成長を大きく牽引しており、これは市場予測期間を通じて継続すると予想されます。

不妊症の発生率の上昇は、世界の体外受精（IVF）サービス市場の成長を促進する重要な要因です。このような不妊率の増加は、ここ数十年の間に開発されたさまざまな社会的、経済的、健康関連要因に関連しています。

2024年10月のCofertilityのデータによると、不妊症は世界的に重要な健康問題であり、世界中で約6人に1人が罹患しています。この統計は、地理的・社会経済的な境界を越えた大きな懸念として、不妊症の蔓延を浮き彫りにしています。成人人口の約17.5％が、人生のある時点で不妊を経験しています。

これはおよそ6人に1人の割合であり、不妊症が世界的に数百万人に影響を及ぼす広範な問題であることを示しています。約12％の女性が、妊娠または出産に至るまで困難な状況に遭遇しています。全体の19％のカップルが、1年間避妊せずに性交渉を行っても妊娠できないです。さらに、無防備な性交渉が2年続いても妊娠できないカップルが10％いることから、不妊症の長期化は多くの人にとって一般的な経験であることがわかります。

不妊症の発生率の増加は、体外受精の需要の高まりに直結しています。妊娠を望むカップルが増えるにつれ、不妊治療クリニックは患者数の増加を経験し、提供するサービスの幅を広げています。生殖補助医療技術の利用率は年率5％から10％で伸びており、不妊症の有効な解決策として体外受精への信頼が高まっていることを反映しています。この動向は、成功率を高め、治療をより効果的にする生殖技術の進歩によってさらに強化されています。

さらに、この体外受精（IVF）サービス市場の成長を後押しするのは、業界の主要企業による技術的進歩や革新的な新製品の発売です。例えば、2023年9月、ドイツのダルムシュタットにあるMerck KGaA社は、不妊治療を受ける従業員に経済的支援を提供することを目的としたFertility Benefits Programを開始しました。このイニシアチブは、従業員の福利厚生を充実させ、不妊に伴う精神的・経済的負担に対処するという同社のコミットメントを反映しています。

また、2023年9月には、生殖医療技術会社AIVFが、ブラジルのゴイアニアにあるペルフェット・クリニックで、初のAI搭載体外受精オペレーティング・システムを開始しました。この大幅な拡大は、体外受精治療に対する世界の需要の高まりに対応したもので、不妊治療の効率と効果を高めることを目的としています。これらすべての要因が、世界の体外受精（IVF）サービス市場に需要をもたらしています。

さらに、先端技術の採用に対する需要の高まりも、体外受精（IVF）サービスの世界市場拡大に寄与しています。

体外受精の高額費用

体外受精にかかる費用の高さは、体外受精（IVF）サービスの世界市場の成長を妨げます。世界の体外受精（IVF）サービス市場は、その成長とアクセシビリティを妨げる様々な抑制要因によって大きな影響を受けています。その中でも、高い治療費、経済的負担、倫理的配慮が最も重要です。

2022年10月のフィアス・ヘルスケアのニュースによると、不妊治療、特に体外受精（IVF）に伴う経済的負担は相当なものです。米国では、1回の体外受精に通常約1万2,000米ドルかかるが、薬や追加の処置を考慮すると、この数字は2万5,000米ドルにまでエスカレートします。多くの患者が1回目の体外受精では妊娠に至らないため、成功の可能性を高めるために平均3～5回の複数回の体外受精を受けることが多いです。

多くの患者が、妊娠を成功させるためには複数回の体外受精が必要であると感じています。調査によると、平均的な患者は約2.3～2.7回の体外受精を受け、その累積費用は5万米ドルを超えることもあります。さらに1周期増えるごとに平均約6,955ドルの費用がかかり、夫婦の経済的負担はさらに大きくなる5。このような状況は、不妊治療への保険適用が限られているか、存在しない地域では特に困難です。体外受精治療をカバーする包括的な保険がないため、多くの夫婦が多額の自己負担に直面しています。体外受精の費用は、地域によって大きく異なります。例えば、大都市圏のクリニックは、地方のクリニックに比べて高い料金を請求することがあります。

このように、上記の要因は世界の体外受精（IVF）サービス市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 不妊症の発生率の増加
  • 抑制要因
    • 体外受精の高額な費用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 治療の種類別

• 従来の体外受精
• 卵細胞質内精子注入法（ICSI）
• ミニ体外受精
• 自然周期体外受精
• フレッシュサイクル体外受精
• 凍結胚移植（FET）
• その他

第7章 エンドユーザー別

• 不妊治療クリニック
• 病院
• その他

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第10章 企業プロファイル

• Virtus Health
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Genea Pty Limited.
• Aksigen
• Shady Grove Fertility
• New Hope Fertility Clinic
• Boston IVF
• Cyprus IVF Centre
• EUVITRO S.L.U.
• Fertility Centers of Illinois
• Houston Fertility Center

第11章 付録

The global in vitro fertilization (IVF) services market reached US$ 24.91 billion in 2024 and is expected to reach US$ 48.04 billion by 2032, growing at a CAGR of 8.6 % during the forecast period 2025-2032.

In Vitro Fertilization (IVF) services is a medical procedure that facilitates fertilization by combining an egg with sperm outside the body, typically in a laboratory environment. The term "in vitro," which translates to "in glass," signifies that the fertilization process occurs in a controlled setting rather than within the human body. The IVF process generally consists of several key steps including ovarian stimulation, egg retrieval, fertilization, embryo culture, and embryo transfer.

IVF services are commonly employed to address various causes of infertility, including advanced maternal age, blocked fallopian tubes, male factor infertility, endometriosis, and unexplained infertility. This procedure has become a vital option for many couples seeking to conceive when faced with challenges related to fertility. These factors have expanded the global in vitro fertilization (IVF) services market.

Market Dynamics: Drivers & Restraints

Increasing Incidence of Infertility

The increasing incidence of infertility is significantly driving the growth of the global in vitro fertilization (IVF) services market, which is expected to continue throughout the market forecast period.

The rising incidence of infertility is a key factor driving the growth of the global in vitro fertilization (IVF) services market. This increase in infertility rates can be linked to a range of social, economic, and health-related factors that have developed over recent decades.

As per the Cofertility data in October 2024, infertility is a significant global health issue, affecting approximately 1 in 6 individuals worldwide. This statistic highlights the prevalence of infertility as a major concern that transcends geographical and socioeconomic boundaries. About 17.5% of the adult population experiences infertility at some point in their lives.

This translates to roughly 1 in 6 individuals, indicating that infertility is a widespread issue affecting millions globally. Approximately 12% of women encounter difficulties either becoming pregnant or carrying a child to term. 19% of all couples are unable to conceive after one year of unprotected sexual intercourse. Furthermore, 10% of couples remain unable to conceive after two years of unprotected sex, indicating that prolonged infertility is a common experience for many.

The increasing incidence of infertility is directly linked to a heightened demand for IVF services. As more couples seek assistance in conceiving, fertility clinics are experiencing a rise in patient volumes and expanding their range of service offerings. The utilization of assisted reproductive technologies has been growing at an annual rate of 5% to 10%, reflecting a growing reliance on IVF as a viable solution for infertility. This trend is further bolstered by advancements in reproductive technology that enhance success rates and make treatments more effective.

Furthermore, key players in the industry technological advancements, and innovative launches that would drive this in vitro fertilization (IVF) services market growth. For instance, in September 2023, Merck KGaA, Darmstadt, Germany, launched a Fertility Benefits Program aimed at providing financial support for employees undergoing fertility treatments. This initiative reflects the company's commitment to enhancing employee well-being and addressing the emotional and financial burdens associated with infertility.

Also, in September 2023, AIVF, a reproductive technology company, launched the first AI-powered IVF operating system at the Perfetto Clinic in Goiania, Brazil. This significant expansion comes in response to the increasing global demand for IVF treatments and aims to enhance the efficiency and effectiveness of fertility care. All these factors demand the global in vitro fertilization (IVF) services market.

Moreover, the rising demand for the adoption of advanced technologies contributes to the global in vitro fertilization (IVF) services market expansion.

High Costs of IVF Procedures

The high costs of IVF procedures will hinder the growth of the global in vitro fertilization (IVF) services market. The global in vitro fertilization (IVF) services market is significantly impacted by various restraints that hinder its growth and accessibility. Among these, high treatment costs, financial burdens, and ethical considerations are paramount.

As per Fierce Healthcare news in October 2022, the financial burden associated with infertility treatments, particularly In Vitro Fertilization (IVF), is substantial. In the U.S., a single IVF cycle typically costs around $12,000, but this figure can escalate to $25,000 when factoring in medications and additional procedures. Given that many patients do not achieve pregnancy on their first attempt, they often undergo multiple cycles averaging between three to five cycles to increase their chances of success.

Many patients find that they require multiple IVF cycles to achieve a successful pregnancy. Research indicates that the average patient undergoes approximately 2.3 to 2.7 cycles, leading to cumulative expenses that can exceed $50,000 over time. Each additional cycle incurs an average cost of around $6,955, further compounding the financial strain on couples5. This situation is particularly challenging in regions where insurance coverage for fertility treatments is limited or nonexistent. Many couples face significant out-of-pocket expenses due to the lack of comprehensive insurance policies that cover IVF treatments. The cost of IVF can vary significantly based on geographic location. For instance, clinics in major metropolitan areas may charge higher rates compared to those in rural settings.

Thus, the above factors could be limiting the global in vitro fertilization (IVF) services market's potential growth.

Segment Analysis

The global in vitro fertilization (IVF) services market is segmented based on treatment type, end-user, and region.

Treatment Type:

The conventional IVF segment is expected to dominate the global in vitro fertilization (IVF) services market share

The conventional IVF segment holds a major portion of the global in vitro fertilization (IVF) services market share and is expected to continue to hold a significant portion of the global in vitro fertilization (IVF) services market share during the forecast period.

Conventional IVF (c-IVF) remains one of the most widely practiced assisted reproductive technology (ART) methods globally. However, recent years have seen a significant decline in the number of c-IVF procedures, largely due to the increasing preference for intracytoplasmic sperm injection (ICSI), particularly in cases of non-male-related infertility.

According to the NCBI research study in September 2022, infertility affects approximately 48.5 million couples, translating to around 186 million individuals globally. As a result, assisted reproductive technology (ART) has become the most widely recommended solution for those seeking reproductive assistance. Over the past four decades, significant advancements have been made in this field. According to the International Committee for Monitoring ART (ICMART), more than 8 million babies have been born as a result of ART procedures and other advanced fertility treatments since the birth of the first test-tube baby.

Key advancements in ART include improvements in controlled ovarian hyperstimulation, oocyte retrieval techniques, embryonic culture conditions, and freezing procedures, all of which have significantly enhanced human fertility treatments.

One of the most notable technological innovations in ART is intracytoplasmic sperm injection (ICSI), developed to address the low and unpredictable fertilization rates often encountered with conventional in vitro fertilization (c-IVF), particularly in cases involving poor sperm parameters. However, over the last two decades, there has been a rapid increase in the adoption of ICSI, raising questions about its appropriateness in various clinical situations. These factors have solidified the segment's position in the global in vitro fertilization (IVF) services market.

Geographical Analysis

North America is expected to hold a significant position in the global in vitro fertilization (IVF) services market share

As infertility becomes more prevalent, the demand for IVF services continues to rise. Couples facing difficulties in conceiving are increasingly turning to assisted reproductive technologies as viable options. The growing awareness and acceptance of IVF as a solution contribute significantly to market growth.

Infertility has become a significant health issue, affecting approximately 1 in 8 couples in the United States. This statistic highlights the prevalence of infertility, which can result from various factors including age, lifestyle, and medical conditions. Infertility affects a significant portion of the population, with over 10% of women and around 9% of men experiencing infertility issues in the U.S. This rising prevalence drives demand for IVF services as couples seek effective reproductive solutions.

Continuous improvements in reproductive technologies, including controlled ovarian hyperstimulation and embryo culture techniques, have enhanced the success rates of IVF procedures. Innovations such as intracytoplasmic sperm injection (ICSI) have also contributed to better outcomes, especially in cases of male infertility.

Furthermore, key players in the industry have innovative launches and technological advancements that would drive this in vitro fertilization (IVF) services market growth. For instance, in October 2024, Cook Medical announced the launch of its NestVT vitrification device for In Vitro Fertilization (IVF) in the United States. This innovative device is designed to enhance the safety and efficiency of handling embryos and oocytes during the critical processes of vitrification, cryo-storage, and relocation.

Also, in October 2022, Alife Health launched an innovative AI technology aimed at enhancing In Vitro Fertilization (IVF) treatment outcomes while simultaneously lowering costs. This advancement is part of Alife's mission to modernize and personalize the IVF process through the use of artificial intelligence and data-driven insights.

Thus, the above factors are consolidating the region's position as a dominant force in the global in vitro fertilization (IVF) services market.

Asia Pacific holds the fastest pace in the global in vitro fertilization (IVF) services market and is expected to hold most of the market share.

The rise in infertility cases among both men and women is a significant driver for the IVF market. Factors such as sedentary lifestyles, poor dietary habits, and increased exposure to environmental pollutants contribute to this trend. Common conditions like polycystic ovary syndrome (PCOS) and endometriosis further exacerbate infertility rates, leading many couples to seek assisted reproductive technologies like IVF.

Rapid advancements in IVF technologies have significantly improved success rates and treatment effectiveness. Innovations such as controlled ovarian hyperstimulation, embryo culture techniques, and intracytoplasmic sperm injection (ICSI) have enhanced overall outcomes for IVF procedures, making them more appealing to couples facing infertility. Many governments in the region are introducing supportive policies and funding initiatives aimed at promoting reproductive health services, including IVF. This financial backing helps reduce the costs associated with fertility treatments, making them more accessible to a broader population.

India has experienced a notable surge in In Vitro Fertilization (IVF) services, driven by several interrelated factors. This growth reflects changing societal norms, economic conditions, and increasing awareness surrounding fertility treatments.

Furthermore, key players in the industry introducing innovative technologies and government initiatives that would drive this global in vitro fertilization (IVF) services market growth. For instance, In April 2023, Bengaluru-based DYU Healthcare introduced Smart IVF technology, which leverages artificial intelligence (AI) and advanced algorithms to enhance the in-vitro fertilization (IVF) process. This innovative approach aims to significantly improve the chances of successful pregnancies while providing personalized treatment plans tailored to the unique needs of each patient.

Also, in October 2023, the Telangana government inaugurated the first state-run In Vitro Fertilization (IVF) facility at Gandhi Hospital in Secunderabad, marking a significant advancement in public healthcare services for childless couples. This initiative is particularly noteworthy as it provides IVF services free of cost, which include comprehensive investigations, treatment, hormonal therapy, and follow-up care.

Thus, the above factors are consolidating the region's position as the fastest-growing force in the global in vitro fertilization (IVF) services market.

Competitive Landscape

The major global players in the in vitro fertilization (IVF) services market include Virtus Health, Genea Pty Limited., Aksigen, Shady Grove Fertility, New Hope Fertility Clinic, Boston IVF, Cyprus IVF Centre, EUVITRO S.L.U., Fertility Centers of Illinois, and Houston Fertility Center among others.

Key Developments

• In September 2024, MGM Healthcare launched its Varam IVF Centre in Chennai, which aims to provide comprehensive and advanced fertility treatments. This initiative is designed to cater to couples facing infertility challenges by combining specialized medical expertise with state-of-the-art technology and a range of ancillary services, all within one facility.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global in vitro fertilization (IVF) services market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by Connectivity Type
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Incidence of Infertility
  • 4.1.2. Restraints
    • 4.1.2.1. High Costs of IVF Procedures
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Treatment Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 6.1.2. Market Attractiveness Index, By Treatment Type
• 6.2. Conventional IVF *
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Intracytoplasmic Sperm Injection (ICSI)
• 6.4. Mini IVF
• 6.5. Natural Cycle IVF
• 6.6. Fresh Cycle IVF
• 6.7. Frozen Embryo Transfer (FET)
• 6.8. Others

7. By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Fertility Clinics*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Hospitals
• 7.4. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Spain
    • 8.3.5.5. Italy
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. South Korea
    • 8.5.5.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

• 10.1. Virtus Health*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Financial Overview
  • 10.1.4. Key Developments
• 10.2. Genea Pty Limited.
• 10.3. Aksigen
• 10.4. Shady Grove Fertility
• 10.5. New Hope Fertility Clinic
• 10.6. Boston IVF
• 10.7. Cyprus IVF Centre
• 10.8. EUVITRO S.L.U.
• 10.9. Fertility Centers of Illinois
• 10.10. Houston Fertility Center

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us